Jon Congleton - 13 Feb 2025 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Chief Executive Officer, Director
Signature
/s/ Adam Levy, Attorney-in-fact
Issuer symbol
MLYS
Transactions as of
13 Feb 2025
Net transactions value
$0
Form type
4
Filing time
24 Feb 2025, 18:58:52 UTC
Previous filing
15 Jan 2025
Next filing
15 Apr 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Award $0 +570,000 $0.000000 570,000 13 Feb 2025 Common Stock 570,000 $10.20 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month anniversary following the date of grant.